Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AAV vectors for gene correction.

Toni Cathomen1

  • 1Charité Medical School, Institute of Infectious Diseases, Department of Virology, Hindenburgdamm 27, 12203 Berlin, Germany. toni.cathomen@charite.de

Current Opinion in Molecular Therapeutics
|October 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Human gene therapy·2026
Same author

Base editing-derived models of human WDR34 and WDR60 disease alleles replicate retrograde intraflagellar transport (IFT) and hedgehog signaling defects.

Communications biology·2026
Same author

Clinical development of tacrolimus-resistant regulatory T cells to enable simultaneous immunosuppression and immune regulation.

Molecular therapy. Advances·2026
Same author

Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation.

Cell stem cell·2026
Same author

Simultaneous orthogonal cell engineering by a single CRISPR-Cas9 polyfunctional editor.

Nature communications·2026
Same author

ERCC6L2 ensures repair fidelity for staggered-end DNA double-strand breaks.

Nature communications·2026
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Gene correction offers a promising alternative to traditional gene therapy for inherited disorders. This review explores viral gene correction methods, particularly those using adeno-associated virus vectors, for potential clinical applications.

Area of Science:

  • * Molecular Biology
  • * Genetic Engineering
  • * Medical Genetics

Background:

  • * Inherited disorders necessitate permanent genetic mutation correction.
  • * Gene therapy shows success in monogenetic diseases but faces challenges like insertional mutagenesis.
  • * Gene correction emerges as an alternative strategy to repair mutated genes directly.

Purpose of the Study:

  • * To review viral approaches for gene correction.
  • * To specifically examine adeno-associated virus (AAV) vectors in gene correction.
  • * To discuss the future prospects and necessary advancements for clinical gene correction.

Main Methods:

  • * Literature review of viral gene correction technologies.
  • * Focus on adeno-associated virus (AAV) vector systems.

Related Experiment Videos

  • * Analysis of current challenges and future directions in gene correction.

    • Main Results:

    • * Viral vectors, especially AAV, are key for gene correction delivery.
    • * Gene correction offers a direct repair mechanism, avoiding insertional mutagenesis risks.
    • * Significant progress has been made, but challenges remain for widespread clinical use.

    Conclusions:

    • * Viral gene correction, particularly with AAV vectors, holds significant therapeutic potential.
    • * Further research and technological advancements are crucial for clinical translation.
    • * Gene correction represents a vital step towards the ultimate goal of curing inherited disorders.